# Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

> **NCT02568215** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1924 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC01
- **BIOLOGICAL:** Placebo for VRC01

## Key facts

- **NCT ID:** NCT02568215
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-03-03
- **Target enrollment:** 1924 (ACTUAL)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568215, "Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02568215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*